The aim of the present study is to assess the possible modulatory effect of lovastatin (LOVA) on metformin (MET) and gliclazide (GLIC) on pancreatic and cardiovascular complications in rats with experimentally induced diabetes. Male Swiss rats were randomly assigned to seven groups.
.
The standard antidiabetic biguanide drug metformin (MET) is widely popular. It acts as a cellular AMP-activated protein kinase activator, a well-known cellular metabolic sensor. The antihyperglycemic properties of metformin are mainly attributed to its suppression of hepatic glucose production, especially hepatic gluconeogenesis, and slightly increased peripheral tissue insulin sensitivity 4 . MET, independent of its antidiabetic effect, was reported to offer protection against vascular and other inflammatory complications 5 .
The second generation sulfonylurea agent, gliclazide (GLIC), is a common antidiabetic acting by stimulating pancreatic insulin release through binding to specific ATP-sensitive potassium channels 6 . It was reported to possess good antioxidant activity not related to its antidiabetic potential 7 .
Based on the facts listed above, the aim of the present study was to To assess inflammatory and hematological abnormalities, serum Creactive protein (CRP) and interleukin-6 (IL-6) levels, in addition to white blood cells (WBCs) count were measured.
Materials and Method

Animals
Adult male swiss rats (150-180 g) were procured from central animal 
Drugs and Chemicals
Test agents LOVA, GLIC and STZ as well as thiobarbituric acid (TBA), 5,5`-dithio-bis-(2-nitrobenzoic acid) (DTNB), N-(1-Naphthyl) , MET (100 mg/kg/day) 10 , GLIC (20 mg/kg/day) 11 , LOVA plus MET and LOVA plus GLIC, respectively, by oral gavages for 30 consecutive days starting on 4th day after treatment with STZ.
Methodology
Induction of experimental diabetes
Experimental diabetes was induced in 12-hour fasted rats by single i.p. injection of STZ (50 mg/kg). To prevent initial hypoglycemic effect of STZ, animals were given 20% glucose solution for the first 24
hours. Induction of diabetes was confirmed 72 hours after STZ injection through assessment of tail vein blood glucose, after 16 hours of fasting, using a portable glucometer (Accu-Chek, Roche, Germany). Only animals having fasting blood glucose exceeding 250 mg/dl, coupled with diabetic symptoms like polyphagia, polydipsiapolyuria, and weight loss were considered diabetic and included in the study.
After 30 consecutive days of daily drug treatments, rats were lightly anaesthetized with diethyl ether and sacrificed by cervical decapitation. Blood samples were collected in tubes containing EDTA to determine fibrinogen (FBG) and white blood cell (WBCs) count. Serum was obtained after centrifugation at 3000 x g for 20 minutes using a centrifuge (Beckman GS-6 centrifuge, USA), then quickly stored at -80oC and used for assessment of serum levels of triglycerides (TGs), total cholesterol (TC), low density lipoproteincholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), Creactive protein (CRP) and interleukin-6 (IL-6). Pancreas was excised immediately, washed with chilled isotonic saline and stored at -80 oC for preparation of tissue homogenate and slides for histopathology. Tissue homogenates (10% w/v) were prepared in ice cold conditions in a homogenizer (Cole-Parmer instrument, USA) using glass tube and teflon pestle, in phosphate buffer solution. The homogenate was centrifuged at 1000 g for 10 minutes in refrigerated centrifuge and the supernatants obtained were used for assessment of pancreatic tissue levels of thiobarbituric acid reactive substance (TBARS), glutathione reduced (GSH), total nitrite (NO2-), glutathione-S-transferase (GST), superoxide dismutase (SOD) and catalase (CAT). Autopsy samples were taken from pancreas of rats in different groups and fixed in 10% formalin solution in saline to be used for preparation of liver sections for histopathological study. 
Estimation of Biochemical parameters
Statistical analysis
Results are presented as mean ± standard error of mean (SEM). All the statistical analyses were performed using one way analysis of variance (ANOVA) with turkey's post hoc comparison test applied across treatment groups. Significance was based on p value < 0.05.
Data analysis was accomplished using the computer software program statistical package for social sciences (SPSS; version 20).
Results
Administration of STZ to experimental rats resulted in significant Table 3) .
Results of histopathological study showed that STZ administration caused atrophy of islets of Langerhans in addition to perivascular edema and inflammatory infiltration. Treatment with either LOVA, MET or GLIC alone corrected such histopathological features partially, but combination of LOVA with MET or GLIC normalized pancreatic histological architecture ( Fig. 1-7 ).
Discussion
In the present investigation, the modulatory effect of LOVA, a wellknown statin used for treatment of hyperlipidemia, on the beneficial effects of traditional antidiabetics, namely the biguanide drug MET and the sulfonylurea drug GLIC, was studied on adult male Swiss rats with experimental STZ-induced diabetes mellitus (DM) regarding pancreatic and cardiovascular complications. Results of the present work showed that a single i.p. dose of STZ in rats resulted in pancreatic injury evidenced by elevation of blood glucose level coupled with oxidative injury of pancreatic tissue represented as elevated TBARS and NO2-levels and suppressed GSH, GST, SOD and CAT levels ( Table 1) . STZ-induced diabetes was coupled with dyslipidemia as evidenced by derangement HMG-CoA reductase, TGs, TC, LDL-C and HDL-C levels ( Table 2) . STZ-induced diabetes was coupled with inflammatory and hematological disorders represented as elevations of serum CRP and IL-6 levels in addition to elevations of blood FBG level and WBCs count (Table 3) .
Histopathological study strongly supported these biochemical estimations ( Fig. 1-2 ). Results of the present study showed that combination of LOVA with either MET or GLIC to rats significantly reduced STZ-induced pancreatic injury compared to rats receiving either drug alone, evidenced by suppression of blood glucose level coupled with improvements of oxidative markers of pancreatic injury including TBARS, GSH, GST, NO2-and SOD (Table 1) . These results suggest that the beneficial action of LOVA may be related to its antioxidant power, ameliorating diabetes-induced oxidative and nitrosative stress. In harmony with our findings, previous investigators reported protective potential for statins against oxidative and nitrosative stress 42 . This is particularly important as oxidative stress associated with decreased glycemic control has key effects in the pathogenesis of diabetic complications 43 . Nitrosative stress, associated with increased nitric oxide (NO) production, is also an important event in the pathogenesis of diabetic complications. It was previously reported that NO production increases in early stages of diabetes progression, and that inhibition of NO production may be beneficial in antagonizing STZ-induced diabetes 44 .
According to our work results, combination of LOVA with MET or GLIC revealed better improvements of parameters of dyslipidemia, including serum TGs, TC, LDL and HDL, as compared to LOVA, MET or GLIC monotherapies (Table 2) .
These effects are related to cholesterol-lowering effect of LOVA, which is an inhibitor of HMG-CoA reductase enzyme that converts HMG-CoA reductase to mevalonate, the building unit of cholesterol biosynthesis 45 . This hypocholesterolemic effect of LOVA is particularly beneficial in diabetes as it is known to cause dyslipidemia 46 . Dyslipidemia associated with diabetes results from the decreased inhibitory effect of insulin on lipolysis caused by decreased insulin production or increased insulin resistance.
Stimulated lipolysis in adipocytes causes release of free fatty acids, the latter being transported to liver, re-esterified to TGs and and used for assembly of VLDL. Thereafter, serum LDL level increases and HDL level decreases 47 . This diabetic dyslipidemia, known as atherogenic dyslipidemia, is a risk factor for atherosclerosis and consequently many cardiovascular complications48. This strongly supports the idea of adding hypocholesterolemic agents with antidiabetics concerned in the present study.
The present work results showed a significant modulatory potential of LOVA on MET and GLIC effects on serum CRP and IL-6 levels, apparent from significant differences between LOVA plus MET or LOVA plus GLIC groups in comparison with corresponding groups receiving monotherapies (Table 3 ). In agreement, previous investigators reported similar effect of statins on both CRP and IL-6, mostly attributed to beneficial LOVA effect on dyslipidemia49. Effect of LOVA on CRP and IL-6 levels is important in diabetes management as serum CRP and IL-6 levels are indices of acute phase inflammation and early markers of diabetes incidence 50 . CRP is synthesized in the liver under the influence of factors released from adipocytes in dyslipidemic conditions and can exacerbate complement-dependent ischemic necrosis leading to myocardial infarcts 51, 52 . Moreover, the pro-inflammatory cytokine IL-6 is an important mediator in the pathogenesis of diabetes and diabetic complications. It increases peripheral insulin resistance 34 and increases atherosclerotic risk in diabetics 33, 53 . Recently, cytokines were reported not only to be released in response to diabetic inflammatory state, but also to have a mechanistic role in beta islet destruction in diabetes progression, and it was also reported that therapeutic manipulation of cytokines leads to improved glycemic control in diabetics 54 . These findings magnify the beneficial role of LOVA on vascular and even non-vascular diabetic complications.
Results of the present work showed that LOVA combination with either MET or GLIC significantly improved their suppressant effect on blood FBG level ( Table 3 ). The antithrombic effect of statins is attributed to lipid-lowering potential, correcting hemostatic abnormalities resulting from diabetic dyslipidemia 55 . The effect of LOVA on blood FBG level is particularly important in diabetes as hyperfibrinogenemia is a key factor in atherosclerotic and inflammatory complications. FBG mediates platelet cohesion and reversible RBCs aggregation, enhancing atherosclerosis, plaque formation and formation of thrombus over ruptured plaques.
Additionally, FBG degradation products bind LDL, thus enhancing dyslipidemia, and stimulate cell proliferation and migration, thus enhancing inflammatory cascades 37 . Finally, results of the present work revealed that STZ-induced leucocytosis was improved by LOVA addition to MET or GLIC to degrees significantly better than either drug alone (Table 3 ). In agreement, previous authors reported similar effect of statins on lecucocyte count and activation 56 . This effect may be attributed to the fact that statins have the selective ability to inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site 57 . Additionally, the anti-inflammatory and cytokine-lowering effect of statins logically decreases leucocyte activation and proliferation 49, 58 .
Results of histopathological examination were in complete harmony with biochemical findings, where rats co-treated with LOVA plus MET or with LOVA plus GLIC after STZ showed almost normalized pancreatic histology, which is not the case in rats treated with either drug alone (Fig. 3-7) .
Conclusion
Results of the present study conclude that combination of LOVA with conventional antidiabetics has great beneficial effects on diabetesinduced pancreatic and cardiovascular complications, including hyperglycemia, oxidative and nitrosative stress, dyslipidemia, inflammatory disorders, hyperfibrinogenemia and leucocytosis.
These results are promising for further clinical trials and strongly suggest combining LOVA with antidiabetics in clinical cases of DM.
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